Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary) ; Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms ABBY
- Sponsors Genentech; Roche
- 04 Aug 2022 Results (n=184)developing probabilistic deep learning model of AD progression to predict longitudinal outcomes using baseline data from the placebo arm of the ABBY study, presented at the Alzheimer's Association International Conference 2022
- 30 Jul 2021 Results evaluating the Roche Elecsys NeuroToolKit assay panel of 12 cerebrospinal fluid (CSF) biomarkers in patients from a total of six clinical trials of crenezumab and gantenerumab in sporadic Alzheimer's disease presented at the Alzheimer's Association International Conference 2021
- 05 Jun 2019 Results published in the Annals of Neurology